Compare · ASND vs NVO
ASND vs NVO
Side-by-side comparison of Ascendis Pharma A/S (ASND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 14.7x ASND ($13.04B).
- Over the past year, ASND is up 18.7% and NVO is down 40.8% - ASND leads by 59.5 points.
- Both names hit the wire about 11 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Ascendis Pharma A/S
- Novo Nordisk A/S
- Price
- $210.52-3.69%
- $42.94-1.84%
- Market cap
- $13.04B
- $191.82B
- 1M return
- -10.56%
- -6.14%
- 1Y return
- +18.70%
- -40.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 11
- 11
- Recent ratings
- 25
- 25
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ASND
- EVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)
- Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)
- EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)
- Amendment: New insider Smith Scott Thomas claimed ownership of 4,017 units of Ordinary Shares (SEC Form 3)
- Director Bienaime Jean Jacques bought $95,120 worth of Ordinary Shares (400 units at $237.80) (SEC Form 4)
- SEC Form SD filed by Ascendis Pharma A/S
- Citigroup initiated coverage on Ascendis Pharma with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S
- Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates